Q4 2024 Getinge AB Earnings Call Transcript
Key Points
- Order intake grew by 11%, with organic growth of 7.4%, indicating strong demand across most regions and business areas.
- Net sales increased by 11.8% in the quarter, with 9.2% organic growth, driven by healthy price increases and a positive product mix.
- The acquisition of Paragonix Technologies contributed significantly, with a 65% net sales growth in Q4, enhancing Getinge AB's position in the organ transport market.
- Free cash flow increased by more than 70%, reaching approximately SEK1.7 billion, reflecting improved business performance and efficient working capital management.
- The financial position remains solid with a leverage of 1.6 times adjusted EBITDA, well below the internal threshold, supporting a proposed dividend increase to SEK4.60 per share.
- The life science segment experienced flat growth, with weak orders for High Purity New England within bioprocessing.
- A provision of SEK297 million was made for ongoing field actions related to the Cardiosave Balloon Pump, impacting financial results.
- The surgical perfusion product portfolio is being phased out due to declining market share and eroding margins, leading to restructuring costs of approximately SEK800 million.
- Quality-related costs peaked in 2024, exceeding SEK800 million, due to various remediation efforts, impacting profitability.
- Price increases are becoming increasingly difficult to implement in the market, potentially affecting future revenue growth.
Welcome to the Getinge AB Q4 report 2024. (Operator Instructions) Now I will hand the conference over to speakers CEO, Mattias Perjos; and CFO, Agneta Palmér. Please go ahead.
Thank you very much, and welcome, everyone, today to today's earnings call. With me, I have our CFO, Agneta Palmér. Today's conference, we'll start by looking at the performance of Q4, and then do a bit of a recap of some of the key events of 2024.
So we can move directly over to page number 2, please. So the key takeaways when it comes to performance for the quarter, let's start with that. So looking back now at a strong quarter consistent through the three months. Order intake grew by 11%, of which organic growth amounted to 7.4%, thanks to positive development in all our regions and all business areas, except for life science, which was basically flat.
Net sales increased by 11.8% in the quarter, and there was 9.2% organic growth when it came to sales. If you look at the adjusted gross and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
